5807-02-3

Usage

Uses

Used in Pharmaceutical Production:
Morpholinoacetonitrile is used as a key intermediate in the synthesis of various pharmaceuticals. Its reactivity allows for the creation of a wide range of medicinal compounds, contributing to the development of new treatments and therapies.
Used in Agrochemical Synthesis:
In the agrochemical industry, Morpholinoacetonitrile serves as a crucial component in the production of pesticides and other crop protection agents. Its role in these syntheses helps to enhance agricultural productivity and protect crops from pests and diseases.
Used in Fine Chemicals Manufacturing:
Morpholinoacetonitrile is utilized as a reagent in the manufacturing of specialty and fine chemicals, where its unique chemical properties are harnessed to produce high-quality products for various applications.
Used as a Stabilizer in Electroplating Processes:
Morpholinoacetonitrile is employed as a stabilizer in electroplating, where it helps to ensure the uniform deposition of metal coatings and improves the overall quality of the electroplated surfaces.
Used as a Solvent in Specialty Chemicals Production:
In the manufacturing of specialty chemicals, Morpholinoacetonitrile functions as a solvent, facilitating various chemical reactions and aiding in the production of specific chemical compounds.
However, due to its toxic nature and potential to cause irritation to the skin, eyes, and respiratory system, it is imperative to handle Morpholinoacetonitrile with caution and adhere to proper safety measures during its use in various applications.

InChI:InChI=1/C6H10N2O/c7-1-2-8-3-5-9-6-4-8/h2-6H2

Upstream product

• 110-91-8 morpholine 
• 50-00-0 formaldehyd 
• 151-50-8 potassium cyanide 
• 107-16-4 glycolonitrile 
• 74-90-8 hydrogen cyanide 
• 77-78-1 dimethyl sulfate 
• 107-14-2 chloroacetonitrile 
• 590-17-0 cyanomethyl bromide 

Downstream Products

• 2038-03-1 4-(2-AMINOETHYL)MORPHOLINE 
• 200623-49-0 bis(2-morpholinylethyl)amine 
• 3235-82-3 N-morpholylacetic acid ethyl ester 
• 5815-63-4 N-hydroxy-2-(4-morpholinyl)ethanimidamide 
• 5625-98-9 morpholinoethyl amide 
• 71897-59-1 2-[(4-morpholinyl)methyl]pyridine 
• 849682-30-0 4-(2-morpholin-4-ylmethylthiazol-4-yl)benzoic acid 
• 17785-41-0 benzylidene-(2-morpholin-4-yl-ethyl)-amine 
• 2038-05-3 4-(N-benzyl-2-aminoethyl)morpholine 
• 1039332-98-3 2-fluoro-N-(2-morpholinoethyl)-4-nitroaniline 
• 952919-01-6 2-fluoro-N¹-(2-morpholinoethyl)benzene-1,4-diamine 
• 1542259-10-8 3-chloro-N-(2-morpholinoethyl)-4-nitroaniline 
• 1542259-11-9 3-chloro-N¹-(2-morpholinoethyl)benzene-1,4-diamine 
• 1542258-27-4 3-(3-fluoro-4-((2-morpholinoethyl)amino)phenyl)-2,6-dimethylpyrimidine-4(3H)-one 

Relevant academic research and scientific papers

Towards the total synthesis of colletofragarones: constructing the macrocyclic lactone by high pressure-mediated intramolecular Diels-Alder reaction

We report herein an intramolecular Diels-Alder approach towards the construction of the macrocyclic lactone ring and the perhydrobenzofuran system of the colletofragarones, novel metabolites produced by fungi of the genus Colletotrichum that are responsib

Hetero-aromatic compound and its use in medicine

The invention provides a hetero-aromatic compound or a stereisomer, geometric isomer, tautomer, despinner, nitrogen oxide, hydrate, solvate, metabolite, metabolism precursor and pharmaceutically acceptable salt or prodrug thereof, which is used for treating proliferative diseases. The invention also discloses a pharmaceutical composition containing the compound and an application of the compound or pharmaceutical composition thereof in preparation of a medicine for treating proliferative diseases.

Bicyclic alkaloid compound, preparation method and applications thereof

The present invention relates to a bicyclic alkaloid compound, or a tautomer, a stereoisomer, a racemate, the non-equal mixture of enantiomers, a geometric isomer, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutical composition containing the compound. The invention further discloses uses of the compounds and the pharmaceutical composition thereof as drugs, especially as anti-inflammatory drugs and anti-fibrotic drugs.

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The invention relates to the field of medicine, discloses new nitrogen heterocyclic derivatives, preparation method thereof and as medicament in particular as the treatment and prevention of treating tissue fibrosis of the medicament. The invention also discloses a pharmaceutically acceptable compound of the present invention comprise a pharmaceutical composition and methods for using the composition for the treatment of the human or animal tissue fibrosis of diseases, in particular for treating the human or animal renal interstitial fibrosis, glomerular sclerosis, hepatic fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, skin fibrosis, after the operation of adhering, benign prostate hypertrophy, bone-myocardial, scleroderma, multiple sclerosis, pancreas fibrosis, liver cirrhosis, myosarcoma, neurofibromatosis, interstitial pulmonary fibrosis, diabetic nephropathy, Alzheimer's disease or vascular fibrosis disease in use. (by machine translation)

Nitrogenous Heterocyclic Derivatives And Their Application In Drugs

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

POSITIVE RESIST COMPOSITION AND PATTERNING PROCESS

A positive resist composition comprises (A) a resin component which becomes soluble in an alkaline developer under the action of an acid and (B) an acid generator. The resin (A) is a polymer comprising recurring units containing a non-leaving hydroxyl group represented by formula (1) wherein R1 is H, methyl or trifluoromethyl, X is a single bond or methylene, m is 1 or 2, and the hydroxyl group attaches to a secondary carbon atom. The composition is improved in resolution when processed by lithography.

Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K

We have prepared a series of achiral aminoacetonitriles, bearing tri-ring benzamide moieties and an aminocyclohexanecarboxylate residue at P2. This combination of binding elements resulted in sub-250 pM, reversible, selective, and orally bioavailable cathepsin K inhibitors. Lead compounds displayed single digit nanomolar inhibition in vitro (of rabbit osteoclast-mediated degradation of bovine bone). The best compound in this series, 39n (CRA-013783/L-006235), was orally bioavailable in rats, with a terminal half-life of over 3 h. 39n was dosed orally in ovariectomized rhesus monkeys once per day for 7 days. Collagen breakdown products were reduced by up to 76% dose-dependently. Plasma concentrations of 39n above the bone resorption IC50 after 24 h indicated a correlation between functional cellular and in vivo assays. Inhibition of collagen breakdown by cathepsin K inhibitors suggests this mechanism of action may be useful in osteoporosis and other indications involving bone resorption.

Novel tertiary (meth)acrylates having lactone structure, polymers, resist compositions and patterning process

Novel tertiary (meth)acrylate compounds having a lactone structure are polymerizable into polymers having improved transparency, especially at the exposure wavelength of an excimer laser and dry etching resistance. Resist compositions comprising the polymers are sensitive to high-energy radiation, have a high resolution, and lend themselves to micropatterning with electron beams or deep-UV rays.

N-ALKYL AMMONIUM ACETONITRILE SALTS, METHODS THEREFOR AND COMPOSITIONS THEREWITH

A substantially solid composition, the composition having therein a compound with the structure of Formula (I) wherein A, R1, R2, R3, Y and Z are as defined in the disclosure.